Arxxant’s Fate In Question After FDA Requests Additional Trial
This article was originally published in The Pink Sheet Daily
Executive Summary
Lilly may seek a development partner for the diabetic retinopathy treatment to collect the three additional years of efficacy data sought by FDA.
You may also be interested in...
Future Of Lilly’s Arxxant In Doubt
Lilly says it is considering options for the investigational diabetic retinopathy treatment after FDA rejected the company's appeal of a recent "approvable" decision.
Future Of Lilly’s Arxxant In Doubt
Lilly says it is considering options for the investigational diabetic retinopathy treatment after FDA rejected the company's appeal of a recent "approvable" decision.
Lilly Licenses OSI Glucokinase Activator Program For Type 2 Diabetes
The nearly $400 million deal gives Lilly exclusive rights to OSI’s GKA drugs, including a lead compound in Phase I studies.